Company ProfilePremium

HLB Pep Co., Ltd. (formerly Anygen Co., Ltd.)

Company Profile Analysis

Ticker: 196300.KQ펩 주식회사

ESOMAR 23 Corporate BadgeISO Certifications Badge
HLB Pep Co., Ltd. - Company showcase

Year Founded & Workforce

2000

HLB Pep Co., Ltd. logo

HLB Pep Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

HLB Pep Co., Ltd. Overview

Key Facts

ItemDetailSource
Current legal nameHLB Pep Co., Ltd. (HLB펩 주식회사)Biospectator, 1 Apr 2025; Dealsite, 1 Apr 2025
Former nameAnygen Co., Ltd. (애니젠 주식회사)Biospectator; Hankyung, 31 Mar 2026
Origin of former nameTaken from Samsung's "Anycall" handset brand at founding. A promised Samsung investment was later withdrawn because of investment regulations.Hankyung, 31 Mar 2026
Founded2,000PatSnap; CB Insights; company IR deck, May 2025
FounderDr. Kim Jae-il, then a professor at GIST's School of Life SciencesHankyung, 31 Mar 2026
Incorporation jurisdictionRepublic of KoreaInvesting.com profile
HeadquartersGwangju, South Korea.Investing.com; Asia Economy, 30 Jun 2026
Exchange / tickerKOSDAQ (Korea Exchange) / 196300KRX data via StockHub
Listing route and dateTechnology-growth special listing (기술특례). The Korea IR Council report gives December 2016; Aju News gives November 2016.Korea IR Council, 26 Jun 2024; Aju News, 8 Dec 2021
Par valueKRW 500 per shareAju News, 8 Dec 2021
ISIN / CUSIPcheck digit not confirmed). No CUSIP; not US-listed.—
Fiscal year end31 DecemberButler (DART aggregation)
Employees (latest and 3-year trend)——
Auditor——
Market capitalisationAbout KRW 41.0bn at KRW 4,320/share (latest Butler quote). About KRW 44.3bn at KRW 4,665 on 12 Oct 2026 (StockHub).Butler; StockHub
Implied shares outstandingAbout 9.5 million (derived: market cap ÷ share price)Derived
Controlling shareholderHLB Genex Co., Ltd. (HLB제넥스) and related parties: 42.46% after an August 2026 report, down from 42.70%DART large-shareholding report, 20 Aug 2026, via StockHub
Ultimate groupHLB Group, chaired by Jin Yang-gon. HLB Pep is the group's 11th listed affiliate.Smart Today, 10 Mar 2025
WebsiteLegacy: http://www.anygen.com.Input list
Management structureCo-CEO structure from 31 March 2025: Shim Kyung-jae (management) and Kim Jae-il (business). By March 2026 Kim Jae-il was described as CTO.Dealsite, 1 Apr 2025; Hankyung, 31 Mar 2026
Listing status flagDesignated an administrative-issue stock (관리종목) in March 2025. The trigger was pre-tax continuing-operations loss (법차손) above 50% of equity.Bizwatch, 31 Mar 2025; Dailypharm

HLB Pep, formerly Anygen, is Korea's pioneer specialist in synthetic peptides.

Manufacturing base: It says it is the only Korean company with peptide-dedicated GMP facilities for active pharmaceutical ingredients (APIs). It runs two plants:

  • Jangseong, South Jeolla. GMP-certified in 2011, the first in Korea.

  • Osong, North Chungcheong. GMP-certified in 2020.

Scale and revenue: It makes more than 5,000 peptides a year across GMP and non-GMP grades. Revenue comes from custom and research peptides, CDMO work, generic peptide APIs (ganirelix, vasopressin) and a chemical library.

Pipeline: A long-dated drug pipeline spans oncology, infection, metabolic disease and inflammation.

Ownership and funding: HLB Group took control in March 2025 through about KRW 60bn of equity and convertible bond (CB) financing. This ended years of liquidity strain and a minority-shareholder dispute.

Post-acquisition strategy: The company is now pursuing:

  • international API and CDMO sales (Japan, US, Hong Kong);

  • a peptide cosmetics brand (LABSENN);

  • a GLP-1/glucagon dual-agonist obesity programme;

  • a radiopharmaceutical collaboration.

Financial position: The business is still small (FY2025 revenue KRW 5.0bn) and loss-making. Its valuation is tied to HLB Group sentiment and to a KRW 30bn CB overhang.


What the Company Does

HLB Pep designs, synthesises, purifies and supplies peptides — chains of roughly 2 to 50 amino acids — for pharmaceutical, research, cosmetic and industrial uses. Founder Kim Jae-il is credited with helping define that size range in the field (Hankyung, 31 Mar 2026). The business has five lines.

  1. Peptide APIs (GMP). Manufactures pharmaceutical-grade peptide APIs in MFDS-certified GMP plants.

    • Ganirelix (an infertility drug API) is supplied domestically. Its product approval was obtained in 2023 (Korea IR Council, 26 Jun 2024).

    • Vasopressin (an antidiuretic hormone API) was registered on Korea's DMF system in December 2025 and on the US FDA's DMF system in July 2026 (Biospectator, Dec 2025; Finance Scope, 27 Jul 2026; Asia Economy, 20 Aug 2026).

  2. CDMO. Contract process development and manufacturing for drug developers. Korean peptide drug developers that need domestic GMP supply generally use the company, as Hankyung's March 2026 profile notes. Its first disclosed overseas definitive CDMO contract was signed with Japan's PeptiGrowth on 30 June 2026.

  3. Research, custom and catalogue peptides. Non-GMP peptides for academia and industry R&D.

    • Q2 2026 revenue split (Butler, DART-based): CDMO and research peptides 91%, chemical library 9%.
  4. Cosmetic peptide materials and the LABSENN brand.

    • Supplies peptide ingredients.

    • Launched its own derma brand, LABSENN, in 2026. The core ingredient is the patented CMPEP™, a combination of curcumin peptide and marine peptide.

    • First export: four LABSENN products to Romania, announced 7 October 2026.

  5. Proprietary drug discovery. AGM-series candidates in oncology, antiviral, antibacterial, metabolic and inflammatory indications. Most are preclinical; AGM-130 reached Phase 1.

The Company's Own Description

In its May 2025 IR deck, the company calls itself Korea's leading peptide materials developer. It sets out three growth engines:

  • strengthening the core API and CDMO business;

  • building a cosmetics "cash cow";

  • new drug development as "upside potential".

At the May 2025 HLB Forum, CEO Shim Kyung-jae said the company's technology had been undervalued because of past management issues, and that HLB's acquisition had resolved its liquidity problems (Biospectator, 22–23 May 2025).

Independent Characterisation

On the evidence available, HLB Pep is best described as a sub-scale peptide CDMO and API supplier with a venture-style pipeline attached.

Revenue trend: Revenue fell from KRW 10.3bn in FY2021 to KRW 5.0bn in FY2025.

Profitability: Operating losses were KRW 4.3–7.3bn a year in FY2022–FY2025 — a cost base well above revenue.

Disclosed sales mix: Dominated by CDMO and research peptides, so commercial API sales of ganirelix and vasopressin are not yet a separately visible revenue driver.

Strategic value: Its value to HLB Group lies in three things:

  • domestic peptide GMP capacity, which is scarce;

  • optionality on the GLP-1 and peptide-drug supply chain;

  • a platform for group-wide peptide and radiopharmaceutical projects.

Revenue Model

Revenue typeDescriptionDisclosed weight
Product / contract manufacturingCDMO, custom and research peptides, GMP APIs91% of Q2 2026 revenue (CDMO and research peptides combined)
Product (catalogue)Chemical library9% of Q2 2026 revenue
Consumer productsLABSENN cosmetics; launched 2026, first export October 2026—
Licensing / milestonesNo out-licensing revenue identified in sources reviewedNot identified
SubscriptionNot applicable—

Value Chain Position

The company sits upstream as:

  • a peptide synthesis and purification specialist, using solid-phase (SPPS) and solution-phase (SPS) synthesis (IntuitionLabs profile);

  • a GMP API manufacturer;

  • a CDMO for drug developers.

It is also building:

  • a downstream presence in finished consumer cosmetics (LABSENN);

  • early-stage new drug discovery.

Customer Types and End-Markets

Customer typeExamples / evidence
Domestic pharma and biotech drug developersNovacell Technology (described as a long-standing partner on national drug development projects); Cellivery (KRW 0.8bn preclinical supply contract, Sept 2021)
Overseas biotechPeptiGrowth (Japan), CDMO contract June 2026
Overseas distributorsNovaBridge (Hong Kong), sales and business-development MOU June 2026
Research institutions and universitiesResearch and catalogue peptides; joint work with GIST
Finished-dose pharmaGanirelix and vasopressin API buyers. Named customers not disclosed.
Cosmetics buyers and consumersRomanian buyer for LABSENN (October 2026); domestic consumers

End-markets served: pharmaceuticals (peptide therapeutics, including the obesity/GLP-1 class, infertility and critical care); biomedical research; regenerative medicine and cell culture (functional peptides via PeptiGrowth); cosmetics.

Strategy

Stated Corporate Strategy (Paraphrased Themes)

The May 2025 IR deck and the 22 May 2025 HLB Forum set out three pillars:

  1. Strengthen core API and CDMO and expand overseas (Japan, US).

  2. Build a cosmetics cash cow using peptide materials.

  3. Pursue new drug "upside", especially obesity (GLP-1/glucagon dual agonist), then oncology.

Management also pointed to group collaboration — using HLB's marketing and sales capabilities, a point HLB Genex's CEO made at the May 2025 joint IR.

Initiatives Announced in the Last 24 Months

InitiativeCategoryDateDetail
Rename to HLB Pep; co-CEO structureGovernanceMar–Apr 2025New management separates business and management roles
FDA cGMP pursuit (ganirelix)Regulatory / market access2,025Aimed at US sales
Facility investment and CDMO reorganisationOperations2,025Described as large-scale capex and business reorganisation (Biospectator, Dec 2025)
Vasopressin DMF (Korea, then US FDA)Product / regulatoryDec 2025; Jul 2026Global market cited at about USD 2.4bn (company)
Curcumin-based cosmetics → LABSENNNew businessPlanned 2025; launched 2026Four products; exported to Romania October 2026
Oncology pipeline refocusR&DDec 2025Management said it was resetting pipeline direction toward oncology
RayMed RPT co-developmentR&D partnershipJan 2026AGM-330 peptide ligand plus dosimetry/AI platform
Novacell MOUR&D / supplyFeb 2026Oral UC peptide immunotherapy; priority co-development right
PeptiGrowth CDMOCommercialMay–Jun 2026First overseas definitive CDMO contract
NovaBridge MOUSales channelJun 2026Overseas research and industrial peptide sales
Dual-agonist obesity programmeR&DOngoing (national project)Long-acting injectable platform
Automation and process efficiency at OsongOperations2,026Large-scale synthesis and high-difficulty purification capabilities

Other Strategy Items

Medium-term financial targets: No quantified revenue or margin guidance was identified in sources reviewed. Management statements are qualitative; for example, CEO Shim said in Dec 2025 that 2026 would mark the start of full-scale growth.

Sustainability / ESG commitments: None identified.

Cost programmes with targets: None identified.

Products & Services

Peptide APIs (GMP)

ProductDescriptionTarget customerStatus / latest milestoneSource
GanirelixGnRH antagonist peptide API used in infertility treatmentKorean finished-dose pharma; potential US buyersKorean product approval 2023; supplied domestically. FDA cGMP review described as forthcoming in July 2025.Korea IR Council; Biospectator, 16 Jul 2025
VasopressinAntidiuretic hormone API. Promotes renal water reabsorption and constricts blood vessels; used as an adjunct vasopressor in critically ill patients.Global sterile injectables makersKorean DMF about December 2025 (company says domestic first). US FDA DMF July 2026.Biospectator, Dec 2025; Finance Scope, 27 Jul 2026
Other generic peptide APIsCompany states "GMP peptides" and "generic peptides" as service linesPharma—CB Insights; Investing.com

The company cited a global vasopressin market of about USD 2.4bn in 2025 (Biospectator, Dec 2025, citing the company).

CDMO and Custom Peptides

OfferingDescriptionTarget customerNotes
Peptide CDMOProcess development, scale-up, GMP manufacture for clinical and commercial supplyDrug developers in Korea; Japan, US and other overseas targetsDefinitive contract with PeptiGrowth (Japan) for next-generation synthetic growth-factor and cytokine peptides used in cell culture and regenerative medicine (30 Jun 2026)
Custom peptides (GMP and non-GMP)Made-to-order synthesis and purification using SPPS and SPSPharma, biotech, academiaMore than 5,000 peptides produced a year (CEO, May 2025)
Catalogue / research peptidesStandard research-grade peptidesResearch labsOverseas distribution supported by NovaBridge (Hong Kong), June 2026
Functional peptidesHigh-complexity peptides for cell culture and regenerative medicineBiotech; cell-therapy developersVia the PeptiGrowth partnership

Chemical Library

OfferingDescriptionShare of revenue
Chemical libraryCompound library supply.9% of Q2 2026 revenue

Cosmetics (LABSENN and Ingredients)

ProductLaunchKey features (company-reported)Source
LABSENN Peptide Calming SerumH1 2026Aimed at inflammatory skin conditions such as acneAsia Economy, 20 May 2026; Finance Scope, 7 Oct 2026
LABSENN Peptide Repair Micro Bubble Essence28 Jul 2026CMPEP™ patented ingredient; cream-in-essence micro-bubble format; 20 peptides plus collagen, adenosine, 8 hyaluronic acids and ceramide. Company-reported human-application test results: elasticity +10.89%, soothing +26.91%, barrier +12.65%.Dailypharm; Asia Economy, 28 Jul 2026
LABSENN Peptide Repair Hydra Sunscreen2,026Part of the 4-product export setFinance Scope, 7 Oct 2026
LABSENN Peptide Repair Barrier Cream2,026Part of the 4-product export setFinance Scope, 7 Oct 2026
CMPEP™ (ingredient)—Patented combination of curcumin (anti-inflammatory/antioxidant) with seaweed-derived marine peptidesAsia Economy, 7 Oct 2026
In development—New anti-inflammatory peptide materials; scalp-care and hair-loss prevention productsAsia Economy, 7 Oct 2026

Proprietary Drug Pipeline

CodeIndication / mechanismLatest reported stageSource / notes
AGM-130Triple-negative breast cancer; first-in-classPhase 1 (reported 2017 and in current third-party profiles).Dealsite, 2017; Investing.com; StockHub
AGM-330Tumour-targeting peptide that binds nucleolin over-expressed on cancer cell membranesResearch. Basis of the RayMed RPT collaboration (Jan 2026).Biospectator, 5 Jan 2026
AGM-331AnticancerPreclinicalInvesting.com
AGM-380Viral infectionPreclinicalInvesting.com
AGM-290Multidrug-resistant bacterial infectionPreclinicalInvesting.com
AGM-212Type 2 diabetesPreclinicalInvesting.com; Dealsite, 2017
AGM-217Type 2 diabetes and obesityPreclinicalInvesting.com
AGM-260Ulcerative colitisPreclinicalInvesting.com
AGM-251Neuropathic painPreclinical (2017).Dealsite, 2017
GLP-1/glucagon dual agonistObesity. Long-acting injectable platform; national research project.Development. In April 2025 management had described an oral formulation goal.Financial News; Finance Scope, 26 Jun 2026; Dealsite, 1 Apr 2025
AGM-330-based RPT (with RayMed)Radiopharmaceutical therapy. HLB Pep supplies the targeting peptide; RayMed handles isotope design, dosimetry and AI-based non-clinical evaluation.Candidate design / preclinicalBiospectator, 5 Jan 2026
Novacell collaborationPeptide immunotherapies, including an oral ulcerative colitis treatment. HLB Pep is raw-material supplier with priority negotiation right for co-development.MOU (Feb 2026); definitive agreement pendingBiospectator, 23 Feb 2026

Financial Narrative

Income Statement (Chartable)

Basis: Butler (DART aggregation).

Notes:

  • Butler states FY2025 revenue fell 20.3% YoY; the derived figure is -19.4%. The gap reflects rounding of the KRW 100M-unit source data.

Third-Party Ratio Snapshots (Conflicting)

Implied book equity is about KRW 23bn (derived: KRW 41.0bn market cap ÷ 1.78x P/B). This is a market-data inference, not a reported figure.

Commentary on Trends, Inflections and Drivers

Revenue erosion through 2023. Revenue fell 46% between FY2021 and FY2023, from KRW 10.3bn to KRW 5.6bn.

  • Contemporary sources point to two causes:

    • chronic funding constraints;

    • a management dispute with minority shareholders, which began around May 2023 and was followed by litigation into January 2024 (IB Tomato; Dealsite).

  • Management later described the company as undervalued because of these management issues (CEO Shim, May 2025).

Partial recovery in FY2024, renewed decline in FY2025.

  • FY2024 revenue recovered to KRW 6.2bn.

  • FY2025 revenue fell to KRW 5.0bn even though HLB's capital arrived in March 2025.

  • Management said in December 2025 that 2025 had been spent on capex, CDMO reorganisation and business restructuring (Biospectator, Dec 2025). This suggests a transition year in which commercial output was not yet prioritised.

Widening operating loss in FY2025.

  • The operating loss rose to KRW 7.3bn, the largest in the five-year window.

Net income inflection in FY2025.

  • The net loss narrowed sharply to KRW 0.6bn against a KRW 7.3bn operating loss.

  • That implies about KRW 6.7bn of net non-operating gains. Possible sources include gains on CB/derivative revaluation, finance income or asset disposals.

  • This matters for listing status. A small pre-tax loss relative to the post-recapitalisation equity base would help the company stay below the 50% 법차손 threshold that triggered the March 2025 designation.

2026 trajectory.

  • Bullstory's 50.9% revenue growth figure, if it reflects TTM to June 2026, implies a meaningful H1 2026 recovery.

  • The Q2 2026 mix (91% CDMO and research peptides) indicates the core service business is still the driver, not APIs or cosmetics.

  • The H1 2026 semi-annual report (filed 13 Aug 2026) should be reviewed for confirmation.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Structure

LevelEntityRelationship

Group apex

HLB Co., Ltd. (KOSDAQ: 028300) / Chairman Jin Yang-gon

Group leadership

Intermediate parent

HLB Genex Co., Ltd. (formerly Genofocus; industrial enzymes)

Largest shareholder of HLB Pep following the April 2025 restructuring

Listed company

HLB Pep Co., Ltd. (KOSDAQ: 196300)

Subject company

Subsidiaries of HLB Pep

None identified in sources reviewed.

—

Segment / Product Line Details

Segment / product line (as reported)ContentsShare of Q2 2026 revenue (%)

CDMO, research peptides

GMP/non-GMP custom peptides, CDMO services, research and catalogue peptides; APIs appear to be included

91

Chemical Library

Chemical library sales

9

Revenue by Segment

SegmentFY2023FY2024FY2025

Total revenue (KRW Bn)

5.66.25.0

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

10.38.75.66.25.0

Operating income (KRW Bn)

-0.3-4.3-6.7-5.4-7.3

Net income (KRW Bn)

-1.7-6.2-9.1-6.8-0.6

Revenue growth YoY (%, derived)

0-15.5-35.610.7-19.4

Operating margin (%, derived)

-2.9-49.4-119.6-87.1-146.0

Net margin (%, derived)

-16.5-71.3-162.5-109.7-12.0

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2021–FY2025

Revenue CAGR (%, derived)

-16.5

Financial Analysis

ItemStatus

Pre-tax income

Relevant to the 법차손 test.

EPS (basic/diluted)

Loss-making in all five years.

Dividends per share

Zero. No dividend identified; StockHub shows 0.00% yield.

Financial Analysis — ROE

IndicatorButlerStockHubBullstoryComment

ROE (%)

-13.9-2.5-8.8

Different periods and methods; none verified against DART

P/B (x)

1.78

1.70–1.82

—

Consistent range

Debt-to-equity (부채비율, %)

——74.1—

Revenue growth (%, TTM basis presumed)

——50.9—

Net margin (%, TTM presumed)

——-37.6—

Financial Analysis — Equity raised in HLB acquisition

ItemAmountDate / statusSource

Equity raised in HLB acquisition

KRW 20bn third-party allotment: KRW 15bn HLB affiliates, KRW 5bn financial investors

Approved 10 Mar 2025

Asia Economy, 11 Mar 2025; Dealsite

CBs issued in HLB acquisition

KRW 40bn: KRW 5bn HLB affiliates, KRW 35bn financial investors

March 2025

Asia Economy, 11 Mar 2025; Smart Today

Outstanding CBs

KRW 30.0bn

As of 31 Mar 2026

Bizwatch, 14 Jul 2026 (FSS data)

Investor put option window

KRW 30.0bn eligible for early redemption

October 2026

Bizwatch, 14 Jul 2026

3rd-series CB conversion request

—

12 Aug 2026

Butler filing list

Decision to acquire own CBs before maturity

—

8 Sep 2026 (major matters report)

Butler filing list

Dimension Details

DimensionStatus

Geographic split (domestic vs export) for three years

In May 2025 the CEO said the business had so far been confined to the domestic market, which implies predominantly Korean revenue.

Country-level revenue

Not publicly identified

Markets

MarketInitiativeDateRevenue impact

Japan

CPHI Japan participation; PeptiGrowth MOU, then definitive CDMO contract

Jul 2025; May–Jun 2026

Contract value not disclosed

United States

Ganirelix FDA cGMP review (pending as of Jul 2025); vasopressin FDA DMF

2025; Jul 2026

No US sales figures disclosed

Hong Kong / North America

NovaBridge MOU for overseas sales and business development

26 Jun 2026

—

Europe (Romania)

LABSENN 4-product export

7 Oct 2026

—

Asia, South America

LABSENN export talks under way

Oct 2026

—

“—” = not publicly disclosed.

Share Price History

DatePrice (KRW)ContextSource

8 Dec 2021

16,600

Market cap about KRW 93bn

Aju News

circa 2023 (month reported as September)

23,650 (peak)

Before Atinum's share sales

IB Tomato

11 Mar 2025

11,890

After HLB acquisition news; two prior upper-limit sessions

Asia Economy

29 Jun 2026

4,605

Before the PeptiGrowth announcement

Asia Economy

10 Jul 2026

4,010

Down 14.32% on the HLB CRL

Asia Economy

23 Jul 2026

3,885—

Bullstory

12 Oct 2026

4,665

Down 10.63% on the day

StockHub

Latest (Oct 2026)

4,320

Market cap about KRW 41.0bn

Butler

52-week range

3,510 – 9,530 (StockHub) / 3,510 – 9,990 (Bullstory)

Sources differ on the high

StockHub; Bullstory

Valuation Multiples

MultipleHLB PepComment

P/B

1.70–1.82x

StockHub / Butler

P/S (trailing FY2025, derived)

8.2x

KRW 41.0bn ÷ KRW 5.0bn

Capital Markets

ItemStatus

Analyst consensus

None. StockHub shows 0 reports. Historical coverage: Kiwoom (2017), Hyundai Motor Securities comment (2021), Korea IR Council sponsored report (Jun 2024).

Dividend history and policy

No dividends identified (0.00% yield)

Buyback authorisations

None identified. Insider purchases by CEO and group chairman in 2026.

Credit ratings (Moody's / S&P / Fitch)

Not publicly disclosed (unrated)

Debt maturity profile

Acquisition CBs: KRW 30.0bn outstanding (Mar 2026); investor put exercisable October 2026; company resolved early acquisition on 8 Sep 2026.

Analyst Conclusions

Management Guidance and Consensus

ItemStatus
Quantitative guidanceNone identified
Qualitative guidanceManagement framed 2025 as a restructuring year and 2026 as the start of full-scale growth (Biospectator, Dec 2025). Global sales growth targeted with Japan and the US as priority markets (CPHI Japan, Jul 2025).
Consensus estimatesNone (no sell-side coverage)

Bull Case

  1. API commercialisation. US FDA DMF registration for vasopressin (Jul 2026) and pursuit of FDA cGMP for ganirelix could turn into US API orders. Against a revenue base of only KRW 5.0bn, a few commercial API contracts would move growth materially.

  2. Scarcity value amid GLP-1 demand. As the only Korean peptide-dedicated GMP API maker, HLB Pep is the natural domestic partner for Korean peptide developers and a beneficiary of GLP-1-driven capacity tightness. Japan's PeptiGrowth contract validates its supplier-audit readiness.

  3. Group support caps downside. HLB Group holds 42.46%, and both the chairman and CEO bought shares in 2026. The group has also shown a pattern of using affiliate funds to absorb CB redemptions elsewhere in the group (Smart Today, Aug 2025). This reduces near-term solvency risk around the October 2026 put.

Bear Case

  1. No proof of commercial traction. Revenue fell 19.4% in FY2025 (derived) despite KRW 60bn of fresh capital, and operating losses widened to KRW 7.3bn. Proof of a commercial turnaround has not yet appeared in audited numbers.

  2. CB overhang larger than revenue. KRW 30bn of CBs exceeds six times FY2025 revenue. Redemption consumes cash; conversion dilutes shareholders. A sector-wide CB put wave is under way (Dailypharm, Sep 2026).

  3. Price driven by group events. The stock trades on HLB Group events rather than its own fundamentals (-14.32% on the 10 Jul 2026 CRL). Listing-status risk under KOSDAQ 법차손 and revenue rules persists if losses do not narrow.

Catalysts and Monitorables (Next 12 Months)

  1. CB resolution. Amount acquired under the 8 Sep 2026 decision; remaining CB balance; funding source (internal cash vs group support vs new financing).

  2. H1 2026 results. Confirm the TTM growth implied by third-party data and the revenue mix by product line.

  3. Listing status. Confirm whether the administrative-issue designation was lifted after FY2025 results. Check the FY2025 법차손/equity ratio.

  4. FY2026 annual results (Mar 2027). First full year post-restructuring.

  5. FDA milestones. Ganirelix cGMP outcome; first US vasopressin API orders.

  6. CDMO pipeline. PeptiGrowth production ramp; further overseas CDMO contracts (NovaBridge leads).

  7. R&D. Obesity dual-agonist preclinical data or IND timing (the 2024 report cited a 2026 Phase 1 IND target); RayMed RPT candidate selection; Novacell definitive agreement.

  8. LABSENN. Sell-through and additional export markets.

  9. Group events. HLB rivoceranib resubmission; IR Day (15 Oct 2026) disclosures.

Analyst Verdict

HLB Pep is a strategically interesting but financially fragile asset.

What the market is paying for. Its core proposition is that it is Korea's only dedicated peptide GMP API manufacturer, with more than two decades of synthesis know-how. That proposition gained relevance as GLP-1 therapies made peptide capacity scarce, and it explains why HLB Group paid about KRW 60bn in equity and CBs for control in March 2025.

What the reported numbers show. On reported figures, the operating business has not yet responded to the recapitalisation:

  • revenue of KRW 5.0bn in FY2025 is below every year from FY2021 to FY2024 except FY2023;

  • the operating loss widened to KRW 7.3bn;

Progress in 2026. The second-year agenda shows tangible progress:

  • a US FDA DMF for vasopressin;

  • a definitive CDMO contract with a Japanese biotech after a supplier audit;

  • a Hong Kong distribution partner;

  • a first consumer export.

These are the right building blocks, but none has yet been quantified in revenue.

Valuation. The equity trades at about 8x trailing sales and about 1.8x book. That is a premium for a loss-making micro-cap, and it rests on group affiliation and peptide-sector optionality rather than earnings.

Near-term swing factor. The CB structure decides the near term. About KRW 30bn was eligible for put in October 2026, and the company resolved to acquire CBs early in September. How that is funded — internal cash, group money or new paper — will shape dilution and solvency perceptions.

Conclusion. HLB Pep is a speculative, event-driven holding whose investment case depends on converting regulatory filings into recurring API and CDMO revenue within the next 12–18 months. Monitoring priorities, in order:

  1. CB settlement;

  2. H1 2026 and FY2026 revenue mix;

  3. listing-status confirmation;

  4. first US API orders.

Absent visible revenue inflection by FY2026 results, the stock is likely to remain a proxy for HLB Group sentiment rather than a standalone peptide CDMO story.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior rolesEducationSource

Shim Kyung-jae (심경재)

CEO (co-CEO, management)

Since 31 Mar 2025

External affairs at Doosan E&C and Samsung S1; joined HLB Group in 2019 as communications team leader; CEO of HLB Neurotobe from 2024

Business, Chung-Ang University

Dealsite, 1 Apr 2025

Kim Jae-il (김재일)

Founder; co-CEO (business) from Mar 2025; described as CTO by Mar 2026

Founder (2000)

Researcher at Mitsubishi Kasei Institute of Life Sciences (Japan); assistant professor at the University of Tokyo; professor at GIST

PhD in biochemistry, University of Tokyo

Dealsite, 1 Apr 2025; Hankyung, 31 Mar 2026

Directors' Remuneration

ItemStatus

Executive compensation

Not individually disclosed in sources reviewed. Korean rules require individual pay disclosure only above KRW 500M.

Board & Management Changes

DateChangeContext

31 Mar 2025

Shim Kyung-jae elected co-CEO

Post-acquisition; HLB-appointed management

By Mar 2026

Kim Jae-il described as CTO

—

Major Shareholders

HolderStakeDateSource

HLB Genex and related parties (incl. Chairman Jin Yang-gon)

42.46%

Report filed 20 Aug 2026 (previously 42.70%)

DART large-shareholding report via StockHub

HLB Genex (initial allotment)

14.16% from a KRW 8bn subscription

March 2025

Smart Today, 10 Mar 2025

HLB Group affiliates combined (initial)

26.6% post-issue

March 2025

Dealsite, 10 Mar 2025

Jin Yang-gon (HLB Group Chairman)

Bought about 22,000 shares, 12–19 Aug 2026

Aug 2026

Asia Economy, 20 Aug 2026

Shim Kyung-jae (CEO)

22,470 shares after buying 2,170

May 2026

Asia Economy, 20 May 2026

Atinum Investment (historical VC)

5.48% (down from 9.4%)

circa 2023

IB Tomato.

Minority shareholders (historical)

61.25%

circa 2023

IB Tomato

Competitive Landscape

Key Competitors

CompetitorCountryOverlap with HLB PepRelative positioning

Bachem Holding AG

Switzerland

Peptide API CDMO (global leader)

Far larger scale; established FDA/EMA commercial supply

PolyPeptide Group AG

Switzerland/Sweden

Peptide API CDMO; generic peptide APIs

Global scale; GLP-1 CDMO exposure

CordenPharma

Germany/EU

Peptide CDMO

Global scale

GL Biochem (Shanghai)

China

Custom, catalogue, pharmaceutical and cosmetic peptides

Direct product-line overlap (identified as a comparable by CB Insights); low-cost competitor

Hybio Pharmaceutical

China

Generic peptide APIs

Competes in generic APIs; regulatory track record in US/EU

WuXi TIDES (WuXi AppTec)

China

Peptide/oligo CDMO

Large-scale CDMO; subject to US geopolitical scrutiny

AmbioPharm

US/China

Peptide API CDMO

Mid-size global CDMO

CPC Scientific

US/China

Peptide API and custom peptides

Mid-size global supplier

Peptron

Korea (KOSDAQ: 087010)

Peptide drug development and long-acting formulation

Korean peptide peer; drug developer rather than API CDMO

Caregen

Korea (KOSDAQ: 214370)

Cosmetic and health peptides

Direct overlap with the LABSENN / cosmetic peptide strategy

Peer Comparison FY2025

MetricHLB Pep (FY2025)Bachem (FY2024)PolyPeptide (FY2024)

Revenue

KRW 5.0bn

About CHF 605M

About EUR 338M

Revenue growth

-19.4% (derived)

——

Operating margin

-146.0% (derived)

——

Recent Developments

The register runs from April 2025 to October 2026, with the 31 March 2025 AGM included as an anchor.

Company Snapshot

$3.5M

Revenue

2000

Founded

Gwangju, South Korea

Headquarters

SWOT Analysis

Strengths

  • Unique domestic GMP position. The company says it is the only Korean producer with peptide-dedicated GMP API facilities, at Jangseong (GMP 2011) and Osong (GMP 2020) (Hankyung, 31 Mar 2026; Korea IR Council, 2024).
  • Production breadth. More than 5,000 peptides produced a year across GMP and non-GMP grades (CEO Shim, May 2025).
  • Regulatory progress on APIs. Ganirelix approved in Korea (2023); vasopressin registered on Korean DMF (Dec 2025) and US FDA DMF (Jul 2026).
  • Founder expertise. The founder is regarded as a first-generation Korean peptide researcher with University of Tokyo and Mitsubishi institute credentials (Hankyung, 2026).
  • Recapitalised with a strategic parent. About KRW 60bn of financing from the HLB acquisition (Mar 2025). HLB Genex and related parties hold 42.46% (Aug 2026).
  • IP base. PatSnap counts 124 patents; the CMPEP™ ingredient is patented.

Weaknesses

  • Shrinking, sub-scale revenue. KRW 10.3bn (FY2021) down to KRW 5.0bn (FY2025); derived CAGR -16.5%.
  • Chronic operating losses. Losses in every year FY2021–FY2025; FY2025 operating margin about -146% (derived).
  • Revenue concentration. 91% of Q2 2026 revenue from CDMO and research peptides; APIs and cosmetics not yet visible as material lines.
  • Listing-status history. Designated an administrative-issue stock in March 2025 under the 법차손 rule (Bizwatch, 31 Mar 2025).
  • CB dependence. KRW 30.0bn of CBs outstanding at Mar 2026 — larger than FY2025 revenue (Bizwatch, Jul 2026).
  • Governance history. A minority-shareholder management dispute and litigation in 2023–2024 (IB Tomato; Dealsite, Jan 2024).

Opportunities

  • US API sales. FDA DMF for vasopressin (Jul 2026) opens supply to US finished-dose makers; the company cites a global market of about USD 2.4bn.
  • Overseas CDMO. The definitive PeptiGrowth contract (Jun 2026) is a reference customer in Japan's regenerative medicine sector.
  • GLP-1/glucagon dual agonist under a national project. Exposure to the obesity class; investors singled it out at the April 2026 IR Day.
  • Radiopharmaceuticals. AGM-330 plus RayMed dosimetry/AI platform; potential to convert other HLB Group assets (RayMed CEO, Jan 2026).
  • Cosmetics internationalisation. Romania export (Oct 2026), with Asia and South America talks under way.
  • Distribution reach. NovaBridge for North America and global research peptides (Jun 2026).

Threats

  • Group contagion. The 10 Jul 2026 rivoceranib CRL coincided with a 14.32% single-day fall in HLB Pep shares.
  • CB put risk. A KRW 30bn put window in October 2026 amid a sector-wide redemption wave (Dailypharm, 14 Sep 2026). The company decided to acquire CBs early on 8 Sep 2026.
  • Low-cost competition. Chinese peptide suppliers (e.g., GL Biochem, Hybio) compete on price.
  • Listing-rule tightening. KOSDAQ revenue thresholds are being raised (Dealsite TV, Apr 2025).
  • Dilution. CB conversions (Aug 2026) and potential future equity raises.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
31 Mar 2025AGM appoints Shim Kyung-jae co-CEO; name change to HLB PepCompletes the change of control
Mar 2025Designated an administrative-issue stock (법차손 criterion) on FY2024 resultsListing-status risk; to be resolved through recapitalisation
Apr 2025Placed under HLB Genex in group restructuringClarifies parent and governance
14 May 2025Joint IR with HLB Genex and HLB NeurotobeFirst capital-markets presentation as HLB Pep
22 May 2025HLB Forum: three growth engines announcedStrategy reset
9–11 Jul 2025CPHI Japan participation; buyer talks on supply and CDMOJapan channel development (led to PeptiGrowth)
Jul 2025Ganirelix FDA cGMP review described as forthcoming; FDA certification targeted for 2025–
~1 Dec 2025Vasopressin Korean DMF registration (company says first in Korea)New API product
Dec 2025Management says 2025 restructuring is on plan; signals 2026 growth; oncology pipeline refocusGuidance tone (qualitative)
5 Jan 2026RayMed MOU on AGM-330 RPTNew modality
8 Jan 2026CEO interview on the RPT strategyElaborates the RPT rationale
23 Feb 2026Novacell MOUSupplier-to-partner positioning
2 Apr 2026HLB Group IR Day (all 10 listed affiliates); investor interest noted in HLB Pep's dual-mechanism obesity drugInvestor visibility
9 Apr 2026Group integrated shareholders' meetingRetail investor communication
H1 2026LABSENN Peptide Calming Serum launchedCosmetics brand launch
May 2026PeptiGrowth MOU signed at Gwangju HQJapan CDMO pipeline
20 May 2026CEO Shim buys 2,170 shares (holding 22,470)Insider confidence signal
27 May 2026Press reports FY2025 revenue of KRW 5.0bn; losses persisting for 3+ yearsFundamentals still weak
26 Jun 2026NovaBridge MOU; Jangseong plant inspectedOverseas distribution
30 Jun 2026PeptiGrowth definitive CDMO contractFirst overseas CDMO contract
10 Jul 2026HLB receives a third FDA CRL for rivoceranib + camrelizumab (cGMP findings at Hengrui's facility). HLB Pep closes down 14.32% at KRW 4,010.Group sentiment contagion
10 Jul 2026Large-shareholding report filedOwnership change disclosure
14 Jul 2026Press flags HLB Pep's KRW 30bn CB put window in October 2026 amid group-wide CB exposure (KRW 356.8bn across 9 affiliates)Liquidity/overhang risk
27 Jul 2026Vasopressin API US FDA DMF registration completedUS supply eligibility
28 Jul 2026LABSENN Micro Bubble Essence launchedPortfolio expansion
12 Aug 20263rd-series CB conversion requestDilution; reduces the debt-like CB balance
12–19 Aug 2026Chairman Jin Yang-gon buys about 22,000 shares; filings on 20 AugGroup support signal
13 Aug 2026H1 2026 semi-annual report filed–
8 Sep 2026Decision to acquire own CBs before maturity–
Sep 2026HLB's lirafugratinib receives FDA approval (reported as the group's first FDA-approved new drug)Group sentiment support (group-level event)
7 Oct 2026LABSENN first export to RomaniaFirst consumer export
12 Oct 2026IR event notice filed (with correction).Volatility
15 Oct 20262026 HLB Group IR Day (second of the year), 10 listed affiliatesNear-term information event

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Revenue by Segment: Total revenue fell from KRW 5,600 Mn in FY2023 to KRW 5,000 Mn in FY2025.
HLB Pep Co., Ltd. — Revenue by Segment
Series (KRW Mn)FY2023FY2024FY2025
Total revenue5,6006,2005,000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Asia Economy (아시아경제): [HLB group acquisition coverage, 11 Mar 2025]( [PeptiGrowth CDMO contract, 30 Jun 2026]( [Chairman Jin share purchase, 20 Aug 2026]( [CEO share purchase, 20 May 2026]( [LABSENN Romania export, 7 Oct 2026]( [LABSENN essence, 28 Jul 2026]( [Osong plant NIFDS visit, 26 Jun 2024]( [GIST patents, 15 Jun 2020]( [Group IR Day, Apr 2026](: core.asiae.co.kr · core.asiae.co.kr · core.asiae.co.kr · core.asiae.co.kr · core.asiae.co.kr · core.asiae.co.kr · view.asiae.co.kr · core.asiae.co.kr · core.asiae.co.kr
  2. Biospectator: [Shim Kyung-jae appointment / rename]( [HLB Forum plan, May 2025]( [CPHI Japan 2025]( [Vasopressin Korean DMF, Dec 2025]( [RayMed MOU, Jan 2026]( [Novacell MOU, Feb 2026]( [Group IR Day announcement](: biospectator.com · biospectator.com · biospectator.com · biospectator.com · biospectator.com · biospectator.com · biospectator.com
  3. Dealsite: [HLB acquires Anygen, 10 Mar 2025]( [Co-CEO structure, 1 Apr 2025]( [Post-rivoceranib growth axes, May 2025]( [RPT interview, Jan 2026]( [Group value-up, May 2026]( [Anygen lawsuits, Jan 2024]( [Peptide market, 2017](: dealsite.co.kr · dealsite.co.kr · dealsite.co.kr · dealsite.co.kr · dealsite.co.kr · dealsite.co.kr · dealsite.co.kr
  4. Hankyung: [Profile of HLB Pep and CEO interview, 31 Mar 2026]( (hankyung.com)
  5. Bizwatch: [KOSDAQ administrative-issue biotech designations, 31 Mar 2025]( [HLB group CB put exposure, 14 Jul 2026]( [Joint IR, 15 May 2025](: news.bizwatch.co.kr · news.bizwatch.co.kr · news.bizwatch.co.kr
  6. Dailypharm: [법차손 designations]( [Biotech CB redemption wave, 14 Sep 2026]( [LABSENN essence]( [PeptiGrowth MOU]( [Group IR Day Oct 2026]( [RayMed MOU](: dailypharm.com · dailypharm.com · dailypharm.com · m.dailypharm.com · m.dailypharm.com · dailypharm.com
  7. Financial News: [NovaBridge MOU, 26 Jun 2026]( (fnnews.com)
  8. Finance Scope: [LABSENN Romania export]( [Novacell MOU]( [NovaBridge MOU]( [Vasopressin FDA DMF tag page](: finance-scope.com · finance-scope.com · finance-scope.com · finance-scope.com
  9. Money Today: [RayMed RPT MOU, 5 Jan 2026]( (mt.co.kr)
  10. Smart Today: [HLB Group acquires Anygen, 10 Mar 2025]( [HLB CB refinancing, Aug 2025](: smarttoday.co.kr · smarttoday.co.kr
  11. IB Tomato: [Anygen minority shareholder dispute]( (newstomato.com)
  12. Aju News: [Anygen share price and pipeline, Dec 2021]( (ajunews.com)
  13. Korea IR Council sponsored report: [Anygen, 26 Jun 2024]( (stock.pstatic.net)
  14. Company IR deck: [HLB Pep business status and outlook, 14 May 2025]( (file.alphasquare.co.kr)
  15. Market data: [Butler (DART aggregation)]( [StockHub]( [StockHub DART summary, 20 Aug 2026]( [Bullstory]( [Simply Wall St](: butler.works · stockhub.kr · stockhub.kr · bullstory.io · simplywall.st
  16. Third-party profiles: [Investing.com]( [PatSnap]( [CB Insights]( [IntuitionLabs](: Investing.com · discovery.patsnap.com · cbinsights.com · intuitionlabs.ai
  17. HLB Group context: [Edaily, HLB CRL, 10 Jul 2026]( [Edaily, September 2026 outlook](: en.edaily.co.kr · en.edaily.co.kr

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.